SIGA Technologies Inc. 8-K Summary
Business Context and Reporting Period
Date: September 2, 2016
Company: SIGA Technologies, Inc.
Event: Entry into a Material Definitive Agreement (Loan and Security Agreement) and issuance of a Warrant.
Status: The agreement is subject to approval by the United States Bankruptcy Court for the Southern District of New York.
Key Financial Metrics and Debt Structure
The filing details a new debt facility rather than reporting operational financial results (revenue, profit, or cash flow) for a specific period.
- Total Term Loan Facility: $80,000,000 (First-priority senior secured).
- Interest Rate: Adjusted LIBO Rate + 11.50% per annum.
- Interest Penalty on Default: +2.00% per annum.
- Collateral: Lien on substantially all tangible and intangible assets, including intellectual property.
- Warrant Issuance: Warrant to purchase shares equal to $4,000,000 divided by the lower of $2.29 or the subscription price of a concurrent equity rights offering. Exercisable for 10 years with weighted average anti-dilution protection.
Material Changes and Fund Allocation
The $80 million Term Loan is structured with specific escrow and reserve requirements, meaning funds are not immediately available for general corporate use:
- Reserve Account (Interest): $25,000,000 held to pay interest on the Term Loan as it becomes due.
- Reserve Account (Conditional): $5,000,000 held; up to the full amount may be withdrawn after June 30, 2018, subject to conditions.
- PharmAthene Judgment Payment: $50,000,000 (net of fees) designated to satisfy the final judgment awarded to PharmAthene, Inc. Funds are released only upon completion of a $35,000,000 equity rights offering and satisfaction of the judgment.
- Escrow Status: Until the "Escrow Release Date," no security is granted, and no covenants or events of default are effective. The Company does not control the escrow account.
Outlook, Risks, and Covenants
Conditions Precedent:
- Bankruptcy Court approval is required for the Loan Agreement and Warrant.
- Completion of a $35,000,000 equity rights offering is required to release funds for the PharmAthene payment.
- Maturity: Earliest of (i) four-year anniversary of the Escrow Release Date, (ii) acceleration events, or (iii) December 1, 2016, if the PharmAthene Judgment is not satisfied by November 30, 2016.
- Prepayment: Subject to a make-whole provision for three and a half years post-Escrow Release Date.
- Minimum cash balance requirements.
- Achievement of regulatory milestones by specific dates.
- Limitations on R&D expenditures, capital expenditures, additional indebtedness, and asset dispositions.
- Failure to satisfy the PharmAthene Judgment by November 30, 2016, could trigger immediate maturity on December 1, 2016.
- Events of default include non-payment, material inaccuracy of representations, and bankruptcy/insolvency.
Investor Verification Checklist
- Confirm whether the United States Bankruptcy Court has approved the Loan Agreement and Warrant.
- Verify the status and expected closing date of the required $35,000,000 equity rights offering.
- Monitor the timeline for the final payment of the PharmAthene Judgment to avoid the December 1, 2016, maturity trigger.
- Review the specific regulatory milestones required by the covenants and the Company's progress toward them.
- Assess the dilution impact of the Warrant based on the final subscription price of the equity rights offering.